Rafael Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (RFL) on November 21, 2021. The filing primarily addresses significant changes in executive leadership and related compensatory arrangements effective in early 2022. The Company is a Delaware corporation with principal executive offices in Newark, New Jersey.
Key Financial Metrics and Related Party Transactions
The filing does not provide consolidated revenue, profit, or cash flow statements for the reporting period. However, it discloses specific financial data regarding related party transactions for Fiscal 2021 and recent capital activities:
- Transition Services Agreement (IDT): IDT billed the Company $415,316 for services and paid $16,840 on the Company's behalf. The Company billed IDT $57,506 for real estate advisory services. As of July 31, 2021, the Company owed IDT $182,257.
- Lease Income (IDT): IDT paid $1.7 million for office rent and parking in Fiscal 2021. As of July 31, 2021, IDT owed the Company $189,053.
- Lease Income (Genie Energy): Billings totaled approximately $226,199 in Fiscal 2021. No amounts were due as of July 31, 2021.
- Rafael Pharmaceuticals Services: The Company billed Rafael Pharma $480,000 for administrative services in Fiscal 2021. As of July 31, 2021, Rafael Pharma owed the Company $600,000.
- Line of Credit: A $25 million credit line was established with Rafael Pharma. $1.9 million was advanced on September 24, 2021, with the remainder funded on October 1, 2021.
- Capital Raises: The Company raised $13 million in December 2020 and approximately $5.0 million in August 2021 through securities purchase agreements.
Material Changes: Executive Leadership
Effective January 31, 2022, the following departures and appointments were announced:
- Resignations: Ameet Mallik resigned as Chief Executive Officer (CEO) and William Conkling departed as Chief Commercial and Business Officer.
- Appointments: Howard Jonas (Chairman of the Board) was elected CEO effective February 1, 2022. Patrick Fabbio (CFO) was elected President in addition to his CFO role.
- Transition: Mr. Mallik will remain as a director and chair a newly established Transition Committee.
Compensation, Risks, and Contingencies
Compensatory Arrangements:
- Patrick Fabbio: Received an amended letter agreement accelerating option vesting to September 30, 2026. Severance includes 6 months' base salary for termination without cause, or 12 months' base salary if termination occurs within six months of a Change of Control. Subject to stockholder approval, he will receive 363,103 restricted shares with a multi-year vesting schedule.
- William Conkling: Departure agreement includes a $90,000 bonus and $225,000 severance payment (six months' base salary).
Risks and Related Party Conflicts:
- Significant related party transactions exist with IDT Corporation, Genie Energy Ltd., and Rafael Pharmaceuticals, Inc., all of which have overlapping board members or controlling interests with Howard Jonas and his family trusts.
- The Company is in the process of merging Rafael Pharma into a wholly-owned subsidiary.
Investor Verification Checklist
- Verify the stockholder approval status of the 2021 Equity Incentive Plan required for Mr. Fabbio's restricted stock grant (scheduled for January 19, 2022).
- Review the full text of the Amended Letter Agreement (Exhibit 10.01) for specific definitions of "Cause" and "Good Reason" regarding severance.
- Monitor the integration of Rafael Pharma following the merger agreement and the utilization of the $25 million line of credit.
- Assess the impact of the CEO transition on the Company's strategic direction, given Mr. Jonas's return to the role after a previous tenure.